Humacyte regains worldwide rights to vascular product from Fresenius in strategic reversal

Filed April 24, 2026 · Period ending April 21, 2026 · ~1 min read

Key Changes

• high

  Humacyte reclaimed exclusive worldwide development and commercialization rights to its 6mm vascular product, reversing Fresenius's ex-U.S. distribution rights. Company now controls global regulatory and commercial strategy directly.

  Item 1.01 verify on EDGAR →
• medium

  New royalty obligation: Humacyte will pay Fresenius low-single-digit royalties on ex-U.S. net sales after a two-year royalty-free period following launch in each country.

  Item 1.01 verify on EDGAR →
• medium

  Existing U.S. royalty obligations unchanged: mid-single to low double-digit rates on domestic net sales continue under the amended agreement.

  Item 1.01 verify on EDGAR →